CDH2 and cancer: After activating EMT, cancer cells exhibit a molecular shift, characterized by decreased expression levels of epithelial markers, such as E‐cadherin, and increased expression levels of mesenchymal markers, such as β‐catenin, N‐cadherin, and fibronectin.24, 26, 27